Andere talen argenx SE

Aandelen

ARGX

NL0010832176

Real Time Euronext Bruxelles Andere beurzen 13:46:36 26-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
345,8 ^EUR	-0,12%		+2,52%	+0,67%

09:18	Groene Brusselse beurs na cijferstroom	AM
24/04	Bel20 levert winsten toch in	AM

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

LE OPINIONI DEGLI ANALISTI DEL GIORNO : Moncler, Boreo, Fugro, STMicroelectronics, Alfen, Iberdrola, Roche, Temenos, Akzo Nobel...	25/04
AVIS D'ANALYSTES DU JOUR : Kering, Carrefour, STMicroelectronics, ArgenX, Ipsen, Accor, Moncler...	25/04
OPINIONES DE LOS ANALISTAS DEL DÍA : Aedas Homes, Almirall, STMicroelectronics, Enagás, Iberdrola, Roche, Temenos, Moncler...	25/04
European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading	17/04
Argenx : argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease	17/04
Argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease	16/04
Argenx SE Announces Data from its Phase 3 ADHERE Trial Evaluating VYVGART Hytrulo in Patients with Chronic Inflammatory Demyelinating Polyneuropathy	16/04
European Equities Traded in the US as American Depositary Receipts Trend Higher in Thursday Trading	04/04
Revolutionizing Targeted Cancer Treatment and Radiotherapy Manufacturing: Actinium Pharmaceuticals (NYSE: ATNM) Trailblazing Journey	28/03
Argenx : argenx Advances Clinical Development of Efgartigimod in Primary Sjogren’s Disease	27/03
Argenx : argenx Announces Annual General Meeting of Shareholders on May 7, 2024	27/03
Argenx Advances Clinical Development of Efgartigimod in Primary Sjogren’s Disease	27/03
Argenx Se Advances Clinical Development of Efgartigimod in Primary Sjogren's Disease	27/03
Argenx Announces Annual General Meeting of Shareholders on May 7, 2024	26/03
Argenx Gets Japanese Regulator's Approval for Intravenous Use of Vyvgart in Primary Immune Thrombocytopenia	26/03
Argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thrombocytopenia	26/03
Argenx SE Announces Approval of Vyvgart (Efgartigimod Alfa) in Japan for Adults with Primary Immune Thrombocytopenia	26/03
Inarrêtables	22/03
European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading	21/03
Les actions en mouvement : ArgenX peut remercier Chugai, Esso flambe	21/03

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Filters

Headlines

Hoest ArgenX, dan krijgt de Bel20 een verkoudheid

20 december 2023 om 15:49 uur